Novartis AG
General ticker "NVSEF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $224.2B (TTM average)
Novartis AG follows the US Stock Market performance with the rate: 38.0%.
Estimated limits based on current volatility of 2.9%: low 138.16$, high 146.54$
Factors to consider:
- Earnings expected soon, date: 2026-01-29 bmo
- Company pays dividends (annually): last record date 2025-03-12, amount 3.98$ (Y2.84%)
- Total employees count: 69068 as of 2000
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [92.78$, 119.08$]
- 2025-12-31 to 2026-12-31 estimated range: [100.84$, 128.38$]
Financial Metrics affecting the NVSEF estimates:
- Negative: with PPE of 12.5 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 28.12 > 18.33
- Positive: 6.63 < Operating cash flow per share per price, % of 8.94
- Positive: Industry inventory ratio change (median), % of -0.49 <= -0.18
- Positive: Return on assets ratio (scaled to [-100,100]) of 10.46 > 6.04
- Positive: 42.53 < Shareholder equity ratio, % of 43.08 <= 64.17
- Positive: 5.42 < Industry operating cash flow per share per price (median), % of 7.82
Short-term NVSEF quotes
Long-term NVSEF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $43,461.00MM | $46,660.00MM | $51,722.00MM |
| Operating Expenses | $35,515.00MM | $36,891.00MM | $37,178.00MM |
| Operating Income | $7,946.00MM | $9,769.00MM | $14,544.00MM |
| Non-Operating Income | $-769.00MM | $-646.00MM | $-904.00MM |
| Interest Expense | $834.62MM | $876.12MM | $1,036.41MM |
| R&D Expense | $9,172.00MM | $11,371.00MM | $10,022.00MM |
| Income(Loss) | $7,177.00MM | $9,123.00MM | $13,640.00MM |
| Taxes | $1,128.00MM | $551.00MM | $1,701.00MM |
| Profit(Loss)* | $6,955.00MM | $14,850.00MM | $11,941.00MM |
| Stockholders Equity | $59,342.00MM | $46,667.00MM | $44,046.00MM |
| Inventory | $7,175.00MM | $5,913.00MM | $5,723.00MM |
| Assets | $117,453.00MM | $99,945.00MM | $102,246.00MM |
| Operating Cash Flow | $14,236.00MM | $14,458.00MM | $17,619.00MM |
| Capital expenditure | $2,239.00MM | $2,753.00MM | $3,814.00MM |
| Investing Cash Flow | $1,468.00MM | $5,596.00MM | $-7,513.00MM |
| Financing Cash Flow | $-20,562.00MM | $-14,278.00MM | $-11,742.00MM |
| Earnings Per Share** | $3.19 | $7.15 | $5.92 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are valid for ticker NVS. EPS are Split Adjusted, recent splits may be reflected with a delay.